Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma
Sachiko Kawana(Sendai Kousei Hospital), Hironobu Sasano(Tohoku University), Ryoko Saito(Tokyo University of Pharmacy and Life Sciences), Jiro Abe(Miyagi Prefectural Hospital Organization), Shunichi Sugawara(Sendai Kousei Hospital), Yuichiro Kimura(Tohoku University), Ikuro Sato(Miyagi Prefectural Hospital Organization), Mareyuki Endo(Tohoku University), Yasuhiro Miki(Eli Lilly (Japan))
Cited by 17
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k